Insider Selling: InspireMD (NYSE:NSPR) Insider Sells $13,205.27 in Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 8,411 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $1.57, for a total value of $13,205.27. Following the completion of the sale, the insider owned 1,166,253 shares of the company’s stock, valued at $1,831,017.21. This trade represents a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shane Thomas Gleason also recently made the following trade(s):

• On Monday, February 2nd, Shane Thomas Gleason sold 2,000 shares of InspireMD stock. The stock was sold at an average price of $1.60, for a total value of $3,200.00.
• On Friday, January 30th, Shane Thomas Gleason sold 2,900 shares of InspireMD stock. The stock was sold at an average price of $1.63, for a total value of $4,727.00.
• On Thursday, January 29th, Shane Thomas Gleason sold 5,000 shares of InspireMD stock. The shares were sold at an average price of $1.65, for a total value of $8,250.00.
• On Wednesday, January 28th, Shane Thomas Gleason sold 12,395 shares of InspireMD stock. The stock was sold at an average price of $1.65, for a total value of $20,451.75.
• On Tuesday, January 27th, Shane Thomas Gleason sold 4,781 shares of InspireMD stock. The stock was sold at an average price of $1.66, for a total value of $7,936.46.
• On Wednesday, January 21st, Shane Thomas Gleason sold 17,593 shares of InspireMD stock. The shares were sold at an average price of $1.62, for a total transaction of $28,500.66.
• On Tuesday, January 20th, Shane Thomas Gleason sold 2,955 shares of InspireMD stock. The stock was sold at an average price of $1.59, for a total transaction of $4,698.45.
• On Friday, January 16th, Shane Thomas Gleason sold 2,250 shares of InspireMD stock. The stock was sold at an average price of $1.61, for a total transaction of $3,622.50.
• On Thursday, January 15th, Shane Thomas Gleason sold 2,909 shares of InspireMD stock. The shares were sold at an average price of $1.58, for a total transaction of $4,596.22.

InspireMD Price Performance

Shares of NYSE NSPR opened at $1.64 on Thursday. The company has a market capitalization of $69.45 million, a P/E ratio of -2.19 and a beta of 0.93. The company has a 50 day simple moving average of $1.81 and a 200-day simple moving average of $2.15. InspireMD, Inc. has a 1 year low of $1.51 and a 1 year high of $3.80.

Analysts Set New Price Targets

Separately, Maxim Group began coverage on InspireMD in a research note on Monday. They issued a “buy” rating and a $6.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $5.00.

Institutional Trading of InspireMD

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NSPR. Rosalind Advisors Inc. lifted its stake in InspireMD by 70.6% during the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after purchasing an additional 1,616,644 shares in the last quarter. Nantahala Capital Management LLC grew its stake in shares of InspireMD by 45.7% in the third quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock valued at $8,137,000 after buying an additional 1,058,467 shares in the last quarter. Aberdeen Group plc raised its holdings in shares of InspireMD by 27.9% in the 4th quarter. Aberdeen Group plc now owns 3,173,364 shares of the company’s stock valued at $5,649,000 after buying an additional 692,247 shares during the period. Parkman Healthcare Partners LLC lifted its stake in InspireMD by 97.6% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock worth $5,882,000 after acquiring an additional 1,205,328 shares in the last quarter. Finally, Velan Capital Investment Management LP boosted its holdings in InspireMD by 137.1% during the 3rd quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company’s stock valued at $5,166,000 after acquiring an additional 1,239,669 shares during the period. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.